Needham & Co Upgrades Cepheid (CPHD) to Buy
More News related to CPHD
- Cepheid (CPHD) Tops Q4 EPS by 13c; Guides Above for Fy10
- Cepheid Reports Fourth Quarter and Full Year 2009 Results
- Trading Radar for 01/28: Amazon.com (AMZN), Microsoft (MSFT), Chubb (CB), AT&T (T), Ford Motor (F), L-3 (LLL) Report
- Jefferies & Co Initiates Coverage on Biotechnology and Drugs/Medical Supply Stocks
- Cepheid Schedules 2009 Fourth Quarter and Full Year Financial Results Announcement and Webcast
More News related to Upgrades
- Soleil Securities Upgrades Zebra Technologies (ZBRA) to Gradually Accumulate; Valuation Call
- UBS Issues Intraday Upgrade on Cimarex Energy (XEC)
- Boenning & Scattergood Upgrades Equinix (EQIX) to Outperform
- Avondale Partners Upgrades ADC Telecommunications (ADCT) to Market Outperform
- Johnson Rice Upgrades Pool Corp (POOL) to Overweight
Needham & Co upgrades Cepheid (Nasdaq: CPHD) from Hold to Buy. Price target $17.
To see more analyst ratings on CPHD Click Here.
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for genetic testing in the clinical molecular diagnostic, industrial, and biothreat markets.
Related Categories
UpgradesStocks Mentioned
+0.28Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
